Table 1 Clinical data of the study sample
Overall | Group 1 | Group 2 | p | |
|---|---|---|---|---|
(n = 82) | (n = 16) | (n = 66) | ||
LAAT or sludge | No changes | |||
Demographics | ||||
Age | 68.1 ± 10.6 | 70.7 ± 8.0 | 67.4 ± 11.1 | 0.516 |
Female gender | 34.1% (28) | 25% (4) | 36.4% (24) | 0.390 |
Body Mass Index (Kg/m2) | 28.3 ± 4.1 | 26.6 ± 2.8 | 28.7 ± 4.3 | 0.100 |
Clinical data | ||||
AF episode duration > 1 month | 61.0% (50) | 93.8% (15) | 53.0% (35) | 0.003 |
CHADS2 | 2.0 ± 1.1 | 2.3 ± 1.4 | 1.9 ± 1.1 | 0.418 |
CHA2DS2-VASc | 3.2 ± 1.6 | 3.7 ± 1.6 | 3.1 ± 1.6 | 0.247 |
Congestive heart failure | 43.9% (36) | 50% (8) | 42.4% (28) | 0.584 |
Hypertension | 80.5% (66) | 93.8% (15) | 77.3% (51) | 0.136 |
Diabetes mellitus | 18.3% (15) | 31.3% (5) | 15.2% (10) | 0.135 |
Previous stroke or TIA | 13.4% (11) | 18.8% (3) | 12.1% (8) | 0.485 |
Vascular disease | 15.9% (13) | 25.0% (4) | 13.6% (9) | 0.264 |
Anti-thrombotic medication | ||||
Aspirin | 22.8% (18) | 37.5% (6) | 19.0% (12) | 0.116 |
Clopidogrel | 12.7% (10) | 25.0% (4) | 9.5% (6) | 0.096 |
Warfarin | 29.1% (23) | 37.5% (6) | 27.0% (17) | 0.408 |
INR in patients treated with warfarin | 2.4 ± 1.0 | 2.8 ± 1.6 | 2.2 ± 0.6 | 0.394 |
Dabigatran or Rivaroxaban* | 15.2% (12) | 18.8% (3) | 14.3% (9) | 0.657 |
Enoxaparin | 35.4% (29) | 25.0% (4) | 37.9% (25) | 0.334 |
Enoxaparin dosage (mg/Kg bid) | 0.9 ± 0.2 | 1.0 ± 0 | 0.9 ± 0.2 | 0.288 |